製品番号: HY-A0013

Bosentan

32 Cited Publications

カスタマーレビュー

Based on 32 publication(s) in Google Scholar

Bosentan is a competitive and dual antagonist of endothelin-1 (ET) for the ET_A and ET_B receptors with K_i of 4.7 nM and 95 nM in human SMC, respectively.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.94%
CAS 番号: 147536-97-8
分子式: C₂₇H₂₉N₅O₆S
分子量:551.61

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

Bosentan 構造式

CAS 番号: 147536-97-8

容量

価格（税別）

在庫状況

数量

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability お問い合わせ Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

バルクお問い合わせ

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 体内実験
- 臨床実験
化学情報
Publications (32)
溶剤 & 溶解度
- 体外
- 体内
プロトコル
純度とドキュメンテーション
参考文献
Help & FAQs
Bioz

生物活性

製品説明

Bosentan is a competitive and dual antagonist of endothelin-1 (ET) for the ET_A and ET_B receptors with K_i of 4.7 nM and 95 nM in human SMC, respectively.

IC₅₀ & Target

Ki: 4.7 nM (ET_A receptor, in human SMC), 95 nM (ET_A receptor, in human SMC)^[1]

Endothelin Receptor アイソフォーム固有の製品をすべて表示 :

ET_A
ET_B

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	67.36 μM Compound: bosentan	Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against human A-375 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 34473510]
B16	IC₅₀	>80 μM Compound: bosentan	Cytotoxicity against mouse B16 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against mouse B16 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 34473510]
CHO	IC₅₀	202 nM Compound: 1	Displacement of [I125]ET1 from recombinant ETB receptor expressed in CHO cells after 2 hrs by TopCount analysis Displacement of [I125]ET1 from recombinant ETB receptor expressed in CHO cells after 2 hrs by TopCount analysis	[PMID: 22862294]
CHO	IC₅₀	280 nM Compound: Bosentan 1	In vitro inhibitory concentration required against [125I]ET1 binding to membranes of CHO cells expressing human ETB receptor In vitro inhibitory concentration required against [125I]ET1 binding to membranes of CHO cells expressing human ETB receptor	[PMID: 12617929]
CHO	IC₅₀	40 nM Compound: Bosentan 1	In vitro inhibitory concentration required against [125I]ET1 binding to membranes of CHO cells expressing human ETA receptor In vitro inhibitory concentration required against [125I]ET1 binding to membranes of CHO cells expressing human ETA receptor	[PMID: 12617929]
CHO	IC₅₀	45 nM Compound: 1	Displacement of [I125]ET1 from recombinant ETA receptor expressed in CHO cells after 2 hrs by TopCount analysis Displacement of [I125]ET1 from recombinant ETA receptor expressed in CHO cells after 2 hrs by TopCount analysis	[PMID: 22862294]
CHO	IC₅₀	8 nM Compound: 1a	Receptor binding affinity was determined in a radioligand binding assay against [125I]ET1 with recombinant human ETA receptor, expressed in baculovirus-infected CHO cells Receptor binding affinity was determined in a radioligand binding assay against [125I]ET1 with recombinant human ETA receptor, expressed in baculovirus-infected CHO cells	10.1016/S0960-894X(97)00400-9
CHO-K1	IC₅₀	195.9 μM Compound: 1	Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 24 hrs by MTT assay Cytotoxicity against CHOK1 cells assessed as decrease in cell viability after 24 hrs by MTT assay	[PMID: 27318985]
CHO-K1	IC₅₀	8.4 nM Compound: Bosentan	Displacement of 125I-labelled endothelin-1 from human ETA receptor expressed in CHOK1 cell membranes Displacement of 125I-labelled endothelin-1 from human ETA receptor expressed in CHOK1 cell membranes	10.1039/C5MD00169B
CHO-K1	IC₅₀	8.9 nM Compound: Bosentan	Antagonist activity at human endothelin receptor subtype A expressed in CHO-K1 cells Antagonist activity at human endothelin receptor subtype A expressed in CHO-K1 cells	[PMID: 22750010]
HepG2	EC₅₀	12.6 μM Compound: Bosentan	Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis Activation of human PXR expressed in human HepG2 (DPX-2) cells assessed as induction of CYP3A4 after 24 hrs by luminescent analysis	[PMID: 20966043]
HepG2	EC₅₀	14.1 μM Compound: Bosentan	Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis Activation of human PXR expressed in human HepG2 (DPX-2) cells after 24 hrs by luciferase reporter gene based luminescent analysis	[PMID: 20966043]
Sf21	IC₅₀	30.6 μM Compound: Bosentan	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	38.1 μM Compound: Bosentan	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf9	IC₅₀	0.08 μM Compound: 6	Displacement of radioligand from ETA receptor (unknown origin) expressed in fall armyworm sf9 cell membranes Displacement of radioligand from ETA receptor (unknown origin) expressed in fall armyworm sf9 cell membranes	[PMID: 27321813]
Sf9	IC₅₀	80 nM Compound: 1a	Receptor binding affinity was determined against [125I]ET1 with recombinant human ETA receptor, expressed in baculovirus-infected Sf9 cells Receptor binding affinity was determined against [125I]ET1 with recombinant human ETA receptor, expressed in baculovirus-infected Sf9 cells	10.1016/S0960-894X(97)00400-9
SK-MEL-28	IC₅₀	53.65 μM Compound: bosentan	Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Cytotoxicity against human SK-MEL-28 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 34473510]

体外実験

Bosentan (BOS) competitively and specifically antagonizes binding of ¹²⁵I-labelled ET-1 to ET_A receptors on human smooth muscle cells (SMC) and ET_B receptors on human placenta cells. The in vitro binding affinity of Bosentan to ET_A receptors on human SMC is 4.7 nM and to ET_B receptors on human SMC or placenta cells is 41 or 95 nM. Bosentan has 67-fold greater selectivity for ET_A than ET_B receptors (mean IC₅₀=7.1 vs 474.8 nM) in an in vitro ¹²⁵I-labeling assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

In hypertensive rats, Macitentan 30 mg/kg further decreases mean arterial blood pressure (MAP) by 19 mm Hg when given on top of Bosentan 100 mg/kg. Conversely, Bosentan given on top of Macitentan fails to induce an additional MAP decrease. In pulmonary hypertensive rats, Macitentan 30 mg/kg further decreases mean pulmonary artery pressure (MPAP) by 4 mm Hg on top of Bosentan, whereas a maximal effective dose of Bosentan given on top of Macitentan does not cause any additional MPAP decrease^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 147536-97-8
性状 Solid
分子量 551.61
分子式 C₂₇H₂₉N₅O₆S
Color White to off-white
SMILES

O=S(NC1=NC(C2=NC=CC=N2)=NC(OCCO)=C1OC3=CC=CC=C3OC)(C4=CC=C(C(C)(C)C)C=C4)=O
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (32)

All WBCell Imaging/StainingIn Vivo Efficacy StudyIF

Sort by:

Journal Impact Factor

J Exp Clin Cancer Res

The extracellular matrix protein type I collagen and fibronectin are regulated by β-arrestin-1/endothelin axis in human ovarian fibroblasts. [Abstract]

2025 Feb 21;44(1):64. PMID: 39985042
Biomater Res

Distinct Roles of Matrigel Enabled the Production of Expandable Hepatoblast and Polarized Hepatocyte Organoids from Human Embryonic Stem Cells under 3-Dimensional Suspension Conditions. [Abstract]

2025 Nov 7:29:0280. PMID: 41209312
Cell Death Dis

The β-arrestin1/endothelin axis bolsters ovarian fibroblast-dependent invadosome activity and cancer cell metastatic potential. [Abstract]

2024 May 22;15(5):358. PMID: 38777849

Bosentan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 May 22;15(5):358. [Abstract]

Bosentan (BOS) (1 μM; 5 min) abolished the increased HOF invasive potential induced by ET-1.

Bosentan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 May 22;15(5):358. [Abstract]

Bosentan (BOS) (1 μM; 5 min) inhibited the enhanced average invasion depth into the ECM of Kuramochi cells and HOFs induced by ET-1.

Bosentan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 May 22;15(5):358. [Abstract]

Bosentan (BOS) (10 mg/kg; i.p.; once daily for 5 weeks) significantly inhibited intraperitoneal spreading of tumors in NOD/SCID mice.

Bosentan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 May 22;15(5):358. [Abstract]

Bosentan (BOS) (10 mg/kg; i.p.; once daily for 5 weeks) markedly reduced the expression of PDGFR and Vimentin in metastatic nodules of NOD/SCID mice.

Bosentan purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 May 22;15(5):358. [Abstract]

Bosentan (BOS) (10 mg/kg; i.p.; once daily for 5 weeks) significantly enhanced the number of apoptotic cells in the tumors of NOD/SCID mice.
Acta Pharmacol Sin

Circulating small extracellular vesicles promote proliferation and migration of vascular smooth muscle cells via AXL and MerTK activation. [Abstract]

2023 May;44(5):984-998. PMID: 36450791
Phytomedicine

Celastrol as an intestinal FXR inhibitor triggers tripolide-induced intestinal bleeding: Underlying mechanism of gastrointestinal injury induced by Tripterygium wilfordii. [Abstract]

2023 Dec:121:155054. PMID: 37738906
Phytomedicine

Potential detoxification effect of active ingredients in liquorice by upregulating efflux transporter. [Abstract]

2019 Mar 15:56:175-182. PMID: 30668338

Bosentan purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2019 Mar 15:56:175-182. [Abstract]

Representative Western blots for P-gp、BCRP、MRP2 in LS-180 treated with six active compounds in liquorice. C: control, P-1: Rifampicin, P-2: Bosentan, S-1: Liquiritin, S-2: Liquiritigenin, S-3: Isoliquiritin, S-4: Isoliquiritigenin, S-5: Glycyrrhetinic acid, S-6: Licochalcone A.
Hypertension

Chronic Elevation of Endothelin-1 Alone May Not Be Sufficient to Impair Endothelium-Dependent Relaxation. [Abstract]

2019 Dec;74(6):1409-1419. PMID: 31630572
Biomed Pharmacother

GKB202 suppresses endothelin-1/ERK signaling in pancreatic cancer cells: Potential implications for circulating tumor cell regulation. [Abstract]

2025 Aug:189:118341. PMID: 40669304
Cell Biol Toxicol

Endothelial ERG alleviates cardiac fibrosis via blocking endothelin-1-dependent paracrine mechanism. [Abstract]

2021 Dec;37(6):873-890. PMID: 33469864
Biochem Pharmacol

Bosentan confers cardioprotection against cisplatin toxicity: Involvement of β-arrestin-linked ETA receptor signaling. [Abstract]

2026 Aug;250(Pt 2):118027. PMID: 42069228
Cells

The Endothelin Receptor Antagonist Macitentan Inhibits Human Cytomegalovirus Infection. [Abstract]

2021 Nov 8;10(11):3072. PMID: 34831300
Am J Physiol Cell Physiol

Redox-sensitive GPCR signaling drives Gq-dependent Ca²⁺ mobilization and cytokine production in human bronchial epithelial cells. [Abstract]

2026 Jun 18. PMID: 42314770
Eur J Pharmacol

tRF-31-PS5P4PW3FJHP inhibits hypoxia-induced proliferation of pulmonary artery endothelial cells by regulating EDN1 splicing via binding to LSM4. [Abstract]

2026 Jan 12:1011:178426. PMID: 41354297
Toxicology

In vitro test battery for testing molecular initiating events in chemical-induced cholestasis. [Abstract]

2025 Jun 3:154210. PMID: 40473197
Toxicology

Drug interaction study of flavonoids toward OATP1B1 and their 3D structure activity relationship analysis for predicting hepatoprotective effects. [Abstract]

2020 May 15;437:152445. PMID: 32259555
Am J Physiol Heart Circ Physiol

Persistent insulin signaling coupled with restricted PI3K activation causes insulin-induced vasoconstriction. [Abstract]

2019 Nov 1;317(5):H1166-H1172. PMID: 31603345
Sci Rep

Involvement of endothelins in neuroprotection of valosin-containing protein modulators against retinal ganglion cell damage. [Abstract]

2022 Sep 28;12(1):16156. PMID: 36171250
Chem Res Toxicol

Inhibitory Effects of Alkaloids on OATP1B1 In Vitro and In Vivo: Prediction for Food/Herb-Drug Interactions and Hepatoprotective Effects Based on Structure-Activity Relationships. [Abstract]

2025 Feb 17;38(2):281-295. PMID: 39899883
Clin Immunol

NETosis promotes chronic inflammation and fibrosis in systemic lupus erythematosus and COVID-19. [Abstract]

2023 Sep:254:109687. PMID: 37419296
Biotechnol Bioeng

An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]

2021 Dec;118(12):4687-4698. PMID: 34478150
BMC Cancer

Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?. [Abstract]

2018 Feb 6;18(1):154. PMID: 29409474
Am J Physiol Endocrinol Metab

Overproduction of endothelin-1 impairs glucose tolerance but does not promote visceral adipose tissue inflammation or limit metabolic adaptations to exercise. [Abstract]

2019 Sep 1;317(3):E548-E558. PMID: 31310581
Curr Issues Mol Biol

Deciphering the Mechanism of Wogonin, a Natural Flavonoid, on the Proliferation of Pulmonary Arterial Smooth Muscle Cells by Integrating Network Pharmacology and In Vitro Validation. [Abstract]

2023 Jan 8;45(1):555-570. PMID: 36661523
J Chromatogr B Analyt Technol Biomed Life Sci

A simple HPLC-UV method for monitoring therapeutic adherence in pulmonary arterial hypertension. [Abstract]

2025 Feb 1:1252:124443. PMID: 39787725
PLoS One

Endothelin Regulates Porphyromonas gingivalis-Induced Production of Inflammatory Cytokines. [Abstract]

2016 Dec 28;11(12):e0167713. PMID: 28030574
Biopharm Drug Dispos

Inhibition of canalicular and sinusoidal taurocholate efflux by cholestatic drugs in human hepatoma HepaRG cells. [Abstract]

2022 Dec;43(6):265-271. PMID: 36195987
Microcirculation

Lymphatic microcirculation profile in the progression of hypertension in spontaneously hypertensive rats. [Abstract]

2022 Oct;29(6-7):e12724. PMID: 34351675
J Toxicol Sci

Validation of a new protocol for a zebrafish MEFL (malformation or embryo-fetal lethality) test method that conforms to the ICH S5 (R3) guideline. [Abstract]

2024;49(8):337-348. PMID: 39098043
bioRxiv

2023 Apr 22.
Patent

US20220317132A1.
Patent

US20220288064A1.
University of Manitoba

2020 Sep.

溶剤 & 溶解度

体外:

DMSO : ≥ 100 mg/mL (181.29 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8129 mL

9.0644 mL

18.1287 mL

5 mM

0.3626 mL

1.8129 mL

3.6258 mL

10 mM

0.1813 mL

0.9064 mL

1.8129 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.75 mg/mL (4.99 mM); Clear solution

Protocol 2

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.75 mg/mL (4.99 mM); Clear solution

Protocol 3

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 4

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 5

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.53 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 2.5 mg/mL (4.53 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

プロトコル

Cell Assay^[2]

Cell viability is evaluated by the trypan blue exclusion test. Human dermal fibroblasts are treated with the indicated concentration of Bosentan (10, 20 and 40 μM). Cell viability is examined at 24 and 48 hours. Stained (dead) and unstained (viable) cells are counted with a hematocytometer^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Rats^[3]
Two-month-old DSS rats and two-month-old Wistar rats are used. Pharmacological effects on mean arterial pressure (MAP) or mean pulmonary arterial pressure (MPAP) and heart rate (HR) are measured up to 120 h after a single gavage at doses ranging from 0.1 to 100 mg/kg (Macitentan) or 3 to 600 mg/kg (Bosentan). To determine whether Macitentan can provide superior pharmacological activity vs. Bosentan, a study is designed in which: 1) Macitentan is administered on top of the maximal effective dose of Bosentan established by the dose-response curve. 2) the same dose of Bosentan is administered on top of the maximal effective dose of Macitentan. The maximal effective dose of the second compound is administered at T_max of the first tested compound.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (284 KB)
SDS (623 KB)
- English - EN (623 KB)
- Français - FR (623 KB)
- Deutsch - DE (623 KB)
- Norwegian - NO (623 KB)
- Español - ES (623 KB)
- Swedish - SV (623 KB)
- Italian - IT (623 KB)
- Portuguese - PT (623 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Dhillon S, et al. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2009;9(5):331-50. [Content Brief]

[2]. Akamata K, et al. Bosentan reverses the pro-fibrotic phenotype of systemic sclerosis dermal fibroblasts via increasing DNA binding ability of transcription factor Fli1. Arthritis Res Ther. 2014 Apr 3;16(2):R86. [Content Brief]

[3]. Iglarz M, et al. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension. Life Sci. 2014 Nov 24;118(2):333-9. [Content Brief]

[4]. Son GY, et al. Endothelin Regulates Porphyromonas gingivalis-Induced Production of Inflammatory Cytokines. PLoS One. 2016 Dec 28;11(12):e0167713. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8129 mL	9.0644 mL	18.1288 mL	45.3219 mL
	5 mM	0.3626 mL	1.8129 mL	3.6258 mL	9.0644 mL
	10 mM	0.1813 mL	0.9064 mL	1.8129 mL	4.5322 mL
	15 mM	0.1209 mL	0.6043 mL	1.2086 mL	3.0215 mL
	20 mM	0.0906 mL	0.4532 mL	0.9064 mL	2.2661 mL
	25 mM	0.0725 mL	0.3626 mL	0.7252 mL	1.8129 mL
	30 mM	0.0604 mL	0.3021 mL	0.6043 mL	1.5107 mL
	40 mM	0.0453 mL	0.2266 mL	0.4532 mL	1.1330 mL
	50 mM	0.0363 mL	0.1813 mL	0.3626 mL	0.9064 mL
	60 mM	0.0302 mL	0.1511 mL	0.3021 mL	0.7554 mL
	80 mM	0.0227 mL	0.1133 mL	0.2266 mL	0.5665 mL
	100 mM	0.0181 mL	0.0906 mL	0.1813 mL	0.4532 mL

Keywords

Bosentan

32 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Bosentan

GPCR/G Protein Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-diabetic Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Drug-Induced Liver Injury (DILI) Compound Library

Anti-Pancreatic Cancer Compound Library

Angiogenesis-Related Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Coagulation and Anti-coagulation Compound Library

Pain-Related Compound Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Mitochondrial Toxicity Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

MedChemExpress（MCE）の使用を引用している文献 Bosentan

Endothelin Receptor アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (32)

溶剤 & 溶解度

プロトコル

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Bosentan 関連分類

製品番号: HY-A0013